|Bid||8.40 x 3100|
|Ask||8.35 x 4000|
|Day's range||7.75 - 8.39|
|52-week range||0.25 - 18.77|
|Beta (5Y monthly)||4.30|
|PE ratio (TTM)||N/A|
|Earnings date||04 Nov 2021 - 08 Nov 2021|
|Forward dividend & yield||N/A (N/A)|
|1y target est||8.88|
Ocugen's share price has skyrocketed roughly seven times more than Novavax's has. Does that make Ocugen the smarter vaccine stock to buy right now? Here are seven reasons why Novavax stock is a no-brainer pick over Ocugen.
What's really interesting about the stock market is there are always new companies trying new things. And sometimes the stocks of these companies come out of nowhere and blow the market averages away.
Beauty is in the eye of the beholder -- and, in many cases, so is the appropriate valuation of a stock. Here's why they picked Cassava Sciences (NASDAQ: SAVA), Ocugen (NASDAQ: OCGN), and Moderna (NASDAQ: MRNA). Prosper Junior Bakiny (Cassava Sciences): Investors have been flocking to this clinical-stage biotech all year long, pushing its share price up by well over 600%.